Antimalarial activity of sera from subjects taking HIV protease inhibitors

• Published in: AIDS (London) Vol. 21; no. 6; pp. 763 - 765
• Main Authors: REDMOND, Andrew M, SKINNER-ADAMS, Tina, ANDREWS, Katherine T, GARDINER, Donald L, RAY, John, KELLY, Mark, MCCARTHY, James S
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 30.03.2007
• Subjects: Animals; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antimalarials - therapeutic use; Antiparasitic agents; Antiretroviral Therapy, Highly Active - methods; Biological and medical sciences; Chloroquine - therapeutic use; Drug Synergism; HIV Infections - blood; HIV Infections - complications; HIV Infections - drug therapy; HIV Protease Inhibitors - therapeutic use; Human immunodeficiency virus; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Lopinavir; Malaria, Falciparum - blood; Malaria, Falciparum - complications; Malaria, Falciparum - drug therapy; Medical sciences; Pharmacology. Drug treatments; Plasmodium falciparum - drug effects; Plasmodium falciparum - growth & development; Pyrimidinones - therapeutic use; Reverse Transcriptase Inhibitors - therapeutic use; Ritonavir - therapeutic use; Saquinavir - therapeutic use; Treatment Outcome; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Antimalarial; Protozoal disease; Antiretroviral agent; Ritonavir; Chloroquine; Saquinavir; Antiviral; Serum; Antirheumatic agent; Human; Immunopathology; Malaria; Enzyme; Lopinavir; Enzyme inhibitor; AIDS; Parasitosis; Immune deficiency; Infection; Peptidases; Treatment; Viral disease; Hydrolases; Parasiticide; Protease inhibitor
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/QAD.0b013e328031f41a

Synergy between HIV and malaria is being increasingly recognized. We examined the antimalarial activity of sera from subjects receiving chloroquine, no drugs or HAART. Sera from subjects taking ritonavir-boosted saquinavir or lopinavir significantly inhibited parasite growth (median of 55 and 69% inhibition, respectively). These results indicate that patients on protease inhibitors may be afforded some protection from malaria. The clinical relevance of these observations will require confirmation in controlled studies in malaria-endemic regions.